Tsumura Posts Higher Sales but Lower Profits, Keeps Full-Year Forecast and Dividend Plan Intact

An announcement from Tsumura & Co ( (JP:4540) ) is now available.

Tsumura & Co. reported consolidated net sales of ¥145.2 billion for the first nine months of the fiscal year ending March 31, 2026, a 6.1% year-on-year increase, but saw declines in profitability, with operating profit down 10.9%, ordinary profit down 9.2%, and profit attributable to owners of parent falling 12.9% to ¥23.2 billion; basic earnings per share dropped to ¥309.60 and the equity ratio weakened to 55.5% as total assets expanded. Despite the profit pressures, the company maintained its dividend policy with an interim payout of ¥68 per share and is forecasting a slight increase in the full-year dividend to ¥144 per share, while keeping its full-year guidance unchanged at ¥198.0 billion in net sales and a 25.1% decline in profit attributable to owners of parent, signaling a cautious stance amid rising costs or other margin challenges but continued commitment to shareholder returns.

The most recent analyst rating on (JP:4540) stock is a Hold with a Yen4584.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.

More about Tsumura & Co

Tsumura & Co. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange Prime Market, best known for manufacturing and selling Kampo (traditional Japanese herbal) medicines and related healthcare products. The company focuses on prescription and over-the-counter herbal formulations for the domestic market, serving hospitals, clinics, and pharmacies as a core supplier in the Japanese herbal medicine segment.

Average Trading Volume: 360,203

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen315.3B

Learn more about 4540 stock on TipRanks’ Stock Analysis page.